Tobira Therapeutics Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 20

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $1.67B

Tobira Therapeutics General Information

Description

Developer of antiviral compounds for treating human immunodeficiency virus (HIV) infection. The company develops TBR-652 and TBR-220 antagonists for the treatment of HIV or AIDS, hepatitis and related infectious conditions.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Acquirer
Corporate Office
  • 701 Gateway Boulevard
  • Suite 300
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Tobira Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 01-Nov-2016 $1.67B 000.00 00.000 Completed Generating Revenue
7. Reverse Merger 05-May-2015 000.00 Completed Clinical Trials - Phase 3
6. IPO 0000 00000 Cancelled Clinical Trials - Phase 3
5. Convertible Debt 09-Mar-2015 0000 000.00 Completed Clinical Trials - Phase 3
4. Debt - General 30-Jun-2014 0000 000.00 Completed Clinical Trials - Phase 3
3. Later Stage VC (Series B) 30-Jul-2012 0000 000.00 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 29-Sep-2010 $21.2M $52.2M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Aug-2007 $31M $31M 000.00 Completed Product Development
To view Tobira Therapeutics’s complete valuation and funding history, request access »

Tobira Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Tobira Therapeutics’s complete cap table history, request access »

Tobira Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of antiviral compounds for treating human immunodeficiency virus (HIV) infection. The company develops TBR-652
Pharmaceuticals
South San Francisco, CA
20 As of 2016
000.00
0.000 0000-00-00
000000&0 000.00

000000

dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000000000000
Pasadena, CA
000 As of 0000
00.000
00000000 00.000

000000

onsequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum
000000000000000
South San Francisco, CA
000 As of 0000
00000
0&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Tobira Therapeutics Competitors (62)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arrowhead Pharmaceuticals Corporation Pasadena, CA 000 00.000 00000000 00.000
Cytokinetics Formerly VC-backed South San Francisco, CA 000 00000 0&0
UCB Corporation Brussels, Belgium 0000 00000 000000 - 000 00000
RedHill Biopharma Formerly VC-backed Tel Aviv, Israel 000 00000 000000000 00000
Galapagos (Biotechnology) Formerly VC-backed Mechelen, Belgium 0000 00.000 000000000 00.000
You’re viewing 5 of 62 competitors. Get the full list »

Tobira Therapeutics Patents

Tobira Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2017321594-A1 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate Inactive 31-Aug-2016 0000000000
US-10301287-B2 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate Active 31-Aug-2016 0000000000 00
EP-3506896-A1 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate Pending 31-Aug-2016 0000000000
JP-2022137223-A Solid form of senicrivirocumesylate and process for producing solid form of senicrivirocumesylate Pending 31-Aug-2016 0000000000 0
US-20180057481-A1 Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate Active 31-Aug-2016 C07D403/12 0
To view Tobira Therapeutics’s complete patent history, request access »

Tobira Therapeutics Board Members (11)

Name Representing Role Since
Carol Brosgart MD Self Board Member 000 0000
Gwen Melincoff Self Board Member 000 0000
Jeffrey Cooper Self Board Member 000 0000
You’re viewing 3 of 11 board members. Get the full list »

Tobira Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Tobira Therapeutics Former Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ATEM Capital Venture Capital Minority 000 0000 000000 0
Abingworth Venture Capital Minority 000 0000 000000 0
Andera Partners PE/Buyout Minority 000 0000 000000 0
BVF Partners Hedge Fund Minority 000 0000 000000 0
Canaan Partners Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 14 investors. Get the full list »

Tobira Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Regado Biosciences 05-May-2015 0000000000 Biotechnology
To view Tobira Therapeutics’s complete acquisitions history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »